Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COX-2 Inhibitor Meeting Expands To Three Days; GI/Cardiac Safety On Agenda

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA advisory committees will consider overall benefit-risk of COX-2s and related products, both gastrointestinal safety and cardiovascular effects. The meeting will be held Feb. 16-18.

You may also be interested in...



COX-2 Safety Review Will Explore Possible Mechanisms To Explain Risk

Briefing materials for advisory committee meeting suggest that FDA believes cardiovascular safety issues with Vioxx represent a class effect. Committee will be asked for views on whether COX-2s should stay on the market – after being reminded of "hope" for GI safety advantage that drove development.

COX-2 Safety Review Will Explore Possible Mechanisms To Explain Risk

Briefing materials for advisory committee meeting suggest that FDA believes cardiovascular safety issues with Vioxx represent a class effect. Committee will be asked for views on whether COX-2s should stay on the market – after being reminded of "hope" for GI safety advantage that drove development.

COX-2 Safety Fallout Brings Increased Generic Scripts, OTC Use, CVS Says

CVS is seeing increased use of generic and over-the-counter pain medications due to safety concerns about COX-2 inhibitors

Related Content

Topics

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel